Financial Performance - The company reported a total revenue of RMB 3.5 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The gross profit margin for the first half of 2022 was 30%, compared to 28% in the same period last year[1]. - The company achieved operating revenue of RMB 17,756,257,999.12 in the first half of 2022, representing a year-on-year increase of 68.52%[17]. - Net profit attributable to shareholders reached RMB 4,635,749,253.06, up 73.29% compared to the same period last year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 81.00%, amounting to RMB 3,849,967,805.01[19]. - The net cash flow from operating activities was RMB 3,995,746,917.71, reflecting an 86.48% increase year-on-year[20]. - Basic earnings per share rose to RMB 1.59, a growth of 72.83% compared to the previous year[18]. - Diluted earnings per share increased to RMB 1.48, representing a 62.64% rise year-on-year[18]. - The company announced an increase in its full-year revenue growth target from 65-70% to 68-72% due to strong confidence in future growth[47]. Client and Market Expansion - The number of active clients increased by 12% year-on-year, reaching 1,200 clients by June 30, 2022[1]. - The company plans to expand its service offerings in the Asia-Pacific region, targeting a 20% market share by 2025[1]. - Revenue from US clients reached RMB 11.909 billion, up 104% year-on-year, while revenue from Chinese clients was RMB 3.175 billion, growing by 27%[36]. - The company added over 650 new clients in the first half of 2022, serving a total of over 5,850 clients from more than 30 countries, with the top 20 global pharmaceutical companies accounting for approximately 44.2% of total revenue[32]. - The company has effectively implemented business continuity plans in response to COVID-19 measures, ensuring the achievement of overall performance targets[17]. Research and Development - Research and development expenses increased by 25% year-on-year, totaling RMB 500 million, reflecting the company's commitment to innovation[1]. - The company has launched two new drug development platforms, which are expected to enhance service efficiency by 30%[1]. - The company focuses on high-quality and efficient R&D services to enhance client development efficiency across various sectors, including chemical drug development and production, cell and gene therapy, and medical device testing[23]. - The company completed 9 IND applications and received 19 clinical trial approvals in the first half of 2022[45]. - The company has 30 TESSA™ projects under client evaluation, with TESSA™ technology enabling the production of AAV at a scale 10 times greater than traditional methods[44]. Financial Health and Assets - The company's total assets reached RMB 61,913,467,431.70, a 12.31% increase from the end of the previous year[17]. - The net assets attributable to shareholders were RMB 42,080,433,441.88, reflecting a 9.32% increase compared to the end of the previous year[17]. - The company's investment income decreased by 77.86% to RMB 23,297.90 million, primarily due to reduced disposals of non-current financial assets[56]. - Other income increased by 40.83% to RMB 161,157,968.22, mainly due to higher government subsidies related to daily operations[55]. - The company’s total operating costs rose in line with revenue growth, with operating costs amounting to RMB 11,319,309,054.66, a 70.49% increase year-on-year[52]. Environmental Compliance and Management - The company has a total emission of SO₂ at 0.078 tons and NOx at 3.21 tons, with the approved emission limits being 0.2000 tons/year for SO₂ and 6.570 tons/year for NOx, indicating compliance with environmental standards[97]. - The company reported a total of 2.452 tons of non-methane total hydrocarbons (NMHC) and 0.593 tons of COD, with annual emissions of 3.142 tons for NMHC and 131.13 tons for COD, demonstrating effective waste management practices[97]. - The company has established a robust environmental management system, ensuring compliance with pollution discharge standards across its various subsidiaries[97]. - The company is actively monitoring and managing its emissions, with a focus on reducing environmental impact and adhering to regulatory requirements[99]. - The company has implemented a monitoring plan for TRVOC and NMHC emissions, with a compliance limit of 40 mg/m³, ensuring adherence to environmental regulations[99]. Risk Management - The company has no significant risks that could materially affect its operations during the reporting period[1]. - The company faces risks from potential declines in demand for pharmaceutical R&D services, which could adversely affect business operations[76]. - Regulatory changes in the pharmaceutical R&D services industry may impact the company's operations if it fails to adapt its strategies accordingly[77]. - Increased competition in the global pharmaceutical R&D services market poses a risk to the company's market position and profitability[78]. - The company has established a robust internal control system to mitigate compliance risks, but challenges remain due to the number of subsidiaries[79]. Employee and Governance - The company has a total of 39,716 employees, with 11,441 holding master's degrees or higher, and 1,294 holding doctoral degrees[25]. - The company has implemented a stock incentive plan, with several announcements regarding stock options and restricted stock grants made throughout 2022[94]. - The company continues to provide updates on the performance and changes related to its stock incentive plans, ensuring transparency for stakeholders[94]. - The actual controllers of the company, including Ge Li and Ning Zhao, have committed to avoid any unfair transfer of benefits to other entities or individuals, ensuring no harm to the company's interests[194]. - The company emphasizes compliance with legal regulations and internal governance to prevent any unauthorized interference in its management activities[196].

Financial Performance - The company's revenue for Q1 2022 reached ¥8,474,419,333.59, representing a year-on-year increase of 71.18%[6] - Net profit attributable to shareholders was ¥1,642,947,345.12, reflecting a growth of 9.54% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥1,714,144,938.66, which is an increase of 106.52% year-on-year[6] - Adjusted net profit under non-IFRS standards was ¥2,052,645,414.94, up by 85.82% from the previous year[6] - Total revenue for Q1 2022 reached ¥8,474,419,333.59, a 71.5% increase from ¥4,950,479,646.73 in Q1 2021[22] - Net profit for Q1 2022 was ¥1,655,950,521.89, up 9.8% from ¥1,507,104,723.57 in Q1 2021[22] - Operating profit for Q1 2022 was ¥2,004,959,729.24, compared to ¥1,697,539,566.19 in Q1 2021, reflecting a growth of 18.1%[22] - Basic earnings per share for Q1 2022 was ¥0.56, up from ¥0.52 in Q1 2021[23] Revenue Breakdown by Segment - The chemistry segment (WuXi Chemistry) generated revenue of RMB 611,796.51 million, up 102.11% from RMB 302,699.57 million in Q1 2021, with small molecule drug discovery services contributing RMB 174,486.09 million, a 46.62% increase[11][12] - The testing segment (WuXi Testing) reported revenue of RMB 127,938.81 million, a 31.70% increase from RMB 97,144.43 million in the same period last year, with laboratory analysis and testing services growing by 39.85%[12] - The biology segment (WuXi Biology) achieved revenue of RMB 53,261.22 million, reflecting a 26.17% increase from RMB 42,213.50 million in Q1 2021, with new molecular types and biopharmaceutical-related revenue growing by 110%[12] - The CTDMO business (WuXi ATU) generated revenue of RMB 29,864.80 million, a 36.99% increase from RMB 21,800.16 million in Q1 2021, with 74 projects receiving development and production services[12][13] - The domestic new drug development services (WuXi DDSU) reported revenue of RMB 24,062.85 million, down 21.57% from RMB 30,680.69 million in the previous year, due to business upgrades to meet higher client demands[13] Cash Flow and Assets - The net cash flow from operating activities was ¥497,469,053.50, showing a decrease of 25.62% compared to the same period last year[6] - The total assets as of March 31, 2022, amounted to ¥57,582,930,874.69, a 4.45% increase from the previous year[7] - The total current assets as of March 31, 2022, amount to ¥23,039,625,152.46, an increase from ¥21,985,648,602.33 in the previous year[20] - The company's cash and cash equivalents decreased to ¥7,026,897,217.80 from ¥8,238,772,782.53 year-over-year[19] - The total liabilities as of March 31, 2022, are ¥16,935,154,066.16, compared to ¥16,369,925,768.22 in the previous year[20] - The company reported a significant increase in accounts receivable, rising to ¥6,389,675,898.80 from ¥4,619,550,091.65[19] - The inventory as of March 31, 2022, is ¥6,414,769,393.91, compared to ¥5,905,005,712.92 in the previous year[19] Operational Efficiency and Strategy - The company continues to enhance its CRDMO and CTDMO business strategies to improve operational efficiency and capacity utilization[9] - The increase in revenue is attributed to the optimization of operational efficiency and the realization of scale effects[9] - The company completed over 90,000 custom compound syntheses in Q1 2022, enhancing early-stage small molecule drug development for clients[12] - The company expects to achieve a revenue growth of 63-65% in Q2 2022, contingent on the control of the COVID-19 situation in Shanghai and stable global pharmaceutical industry conditions[13] - The company launched the TESSA™ technology for scalable production of adeno-associated viruses (AAV), which is reported to produce AAV at ten times the efficiency of plasmid methods[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 206,649[14] - HKSCC NOMINEES LIMITED holds 392,128,463 shares, representing 13.27% of total shares[14] Research and Development - Research and development expenses increased to ¥280,042,477.39 in Q1 2022, up 37% from ¥204,576,017.34 in Q1 2021[22] - The company has a total of 1,808 new drug molecules in its chemistry service projects, with 49 in Phase III, 271 in Phase II, and 1,446 in Phase I and preclinical stages[12]

[Company Overview](index=4&type=section&id=Item%20II.%20Company%20Overview) The company provides integrated new drug discovery, development, and manufacturing services globally through its unique CRDMO and CTDMO models [Company Overview](index=4&type=section&id=Item%20II.%20Company%20Overview) WuXi AppTec offers integrated, end-to-end new drug discovery, development, and manufacturing services globally via its unique CRDMO and CTDMO models, serving over 5,800 clients - The company provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry through its unique CRDMO (Contract Research, Development, and Manufacturing) and CTDMO (Contract Testing, Research, Development, and Manufacturing) business models[4](index=4&type=chunk) - As of the end of the reporting period, the company served over **5,800 active clients** from more than **30 countries** through **31 global operating bases** and branches[4](index=4&type=chunk) Employee Composition as of Q1 2022 | Position | Asia | US | Europe | Total | | :--- | :--- | :--- | :--- | :--- | | R&D | 29,022 | 1,014 | 154 | 30,190 | | Production | 3,660 | 254 | 75 | 3,989 | | Sales | 39 | 89 | 31 | 159 | | Management & Admin | 2,181 | 410 | 68 | 2,659 | | **Total** | **34,902** | **1,767** | **328** | **36,997** | [Financial and Operating Performance](index=5&type=section&id=Item%20III.%20Key%20Financial%20Data) The company reported strong revenue and adjusted net profit growth in Q1 2022, driven by core business expansion, despite a decline in operating cash flow [Key Financial Data for Q1 2022](index=5&type=section&id=1.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2022, the company achieved 8.47 billion CNY in revenue, a 71.18% YoY increase, with net profit attributable to shareholders growing 9.54% due to non-recurring items, while adjusted non-IFRS net profit saw strong growth Key Financial Indicators for Q1 2022 | Indicator | Amount for Reporting Period (CNY) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 8,474,419,333.59 | 71.18% | | Net Profit Attributable to Shareholders of Listed Company | 1,642,947,345.12 | 9.54% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 1,714,144,938.66 | 106.52% | | Adjusted Non-IFRS Net Profit Attributable to Shareholders of Listed Company | 2,052,645,414.94 | 85.82% | | Net Cash Flow from Operating Activities | 497,469,053.50 | -25.62% | | Basic Earnings Per Share (CNY/share) | 0.56 | 7.69% | Reasons for Key Financial Indicator Changes | Item | Change (%) | Primary Reason | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 106.52 | Continuous optimization of operational efficiency led to increased capacity utilization and enhanced economies of scale | | Adjusted Non-IFRS Net Profit Attributable to Shareholders of Listed Company | 85.82 | Continuous optimization of operational efficiency led to increased capacity utilization and enhanced economies of scale | | Net Cash Flow from Operating Activities | -25.62 | Growth in main business collections, coupled with increased customer orders and inventory stocking due to business expansion, led to a significant increase in current period procurement expenditures | - Total non-recurring gains and losses for the reporting period amounted to **-71.2 million CNY**, primarily due to fair value changes and disposal gains/losses from financial assets held for trading[7](index=7&type=chunk) [Operating Analysis by Business Segment](index=8&type=section&id=Analysis%20Notes) In Q1 2022, all business segments experienced growth, with total revenue up 71.2% YoY, primarily driven by WuXi Chemistry's 102.1% growth, while WuXi DDSU saw a 21.6% decline due to business upgrades Operating Revenue by Business Segment for Q1 2022 (Million CNY) | Business Segment | Q1 2022 | Q1 2021 | Change (%) | | :--- | :--- | :--- | :--- | | WuXi Chemistry | 6,118.0 | 3,027.0 | 102.1 | | WuXi Testing | 1,279.4 | 971.4 | 31.7 | | WuXi Biology | 532.6 | 422.1 | 26.2 | | Cell & Gene Therapy CTDMO (WuXi ATU) | 298.6 | 218.0 | 37.0 | | Domestic New Drug Discovery Services (WuXi DDSU) | 240.6 | 306.8 | -21.6 | | **Total** | **8,474.4** | **4,950.5** | **71.2** | [WuXi Chemistry](index=9&type=section&id=化學業務(WuXi%20Chemistry)) WuXi Chemistry revenue grew 102.1% to **6.118 billion CNY**, driven by a 138.1% increase in Process R&D and Manufacturing (D&M) services, with 1,808 new drug molecules served - Small molecule drug discovery (R) services revenue reached **1.745 billion CNY**, a **46.6% YoY increase**; Process R&D and Manufacturing (D&M) services revenue was **4.373 billion CNY**, up **138.1% YoY**[13](index=13&type=chunk) - As of Q1 2022, WuXi Chemistry served a total of **1,808 new drug molecules**, including **49 in Phase III**, **271 in Phase II**, **1,446 in Phase I/pre-clinical**, and **42 approved for launch**[13](index=13&type=chunk) [WuXi Testing](index=10&type=section&id=測試業務(WuXi%20Testing)) WuXi Testing revenue grew **31.7%** to **1.279 billion CNY**, with laboratory analysis and testing services up 39.9%, and drug safety assessment business showing strong 53% YoY growth - Laboratory analysis and testing services revenue was **909 million CNY**, up **39.9% YoY**; Clinical CRO and SMO services revenue was **370 million CNY**, up **15.2% YoY**[14](index=14&type=chunk) - Drug safety assessment business sales revenue increased by **53% YoY**, maintaining its leading position in the Asia-Pacific region, with the WIND integrated service platform signing **47 projects** this quarter[14](index=14&type=chunk) [WuXi Biology](index=11&type=section&id=生物學業務(WuXi%20Biology)) WuXi Biology revenue increased **26.2%** to **533 million CNY**, driven by a **110% YoY growth** in new modalities and biologics-related revenue, which now accounts for 17.6% of segment revenue - New modalities and biologics-related revenue grew **110% YoY**, increasing its proportion of WuXi Biology revenue from **14.6% in 2021 to 17.6% in Q1 2022**[15](index=15&type=chunk) [Cell & Gene Therapy CTDMO (WuXi ATU)](index=11&type=section&id=細胞及基因療法CTDMO業務(WuXi%20ATU)) Cell & Gene Therapy CTDMO (WuXi ATU) revenue grew **37.0%** to **299 million CNY**, providing development and manufacturing services for **74 projects**, including **8 in Phase III clinical trials** - Provided development and manufacturing services for **74 projects**, including **59 pre-clinical/Phase I**, **7 Phase II**, and **8 Phase III projects** (with **4 preparing for NDA submission**)[15](index=15&type=chunk) - In March 2022, the revolutionary TESSA™ technology was officially launched for large-scale production of transfection-free adeno-associated virus (AAV), reportedly achieving **10 times the yield** of traditional plasmid methods[15](index=15&type=chunk) [Domestic New Drug Discovery Services (WuXi DDSU)](index=12&type=section&id=國內新藥研發服務部(WuXi%20DDSU)) Domestic New Drug Discovery Services (WuXi DDSU) revenue decreased **21.6%** to **241 million CNY**, primarily due to proactive business upgrades to meet higher client demands - The revenue decline was primarily due to proactive business upgrades to meet higher client demands for new drug R&D services in China, which had some impact on current period performance[16](index=16&type=chunk) [Performance Outlook](index=12&type=section&id=Performance%20Outlook) Despite the Shanghai outbreak, the company projects **63-65% revenue growth** for Q2 2022 and **65-70% for the full year**, leveraging its global presence and business continuity plans, contingent on pandemic control - If the Shanghai pandemic is effectively controlled by the end of April 2022, the company anticipates **63-65% high-speed revenue growth** in Q2 2022[16](index=16&type=chunk) - The company is confident in achieving **65-70% revenue growth** for the full year 2022, though realization depends on internal and external environmental changes, posing uncertainties[16](index=16&type=chunk) [Shareholder Information](index=13&type=section&id=Item%20IV.%20Shareholder%20Information) This section details the company's shareholder structure, including the total number of shareholders and the top ten holders as of March 31, 2022 [Major Shareholder Holdings](index=13&type=section&id=1.%20Total%20Number%20of%20Common%20Shareholders%20and%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%20and%20Top%20Ten%20Shareholders%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of March 31, 2022, the company had **206,649 common shareholders**, with HKSCC NOMINEES LIMITED being the largest holder at **13.27%** among the top ten - The total number of common shareholders as of the end of the reporting period was **206,649**[17](index=17&type=chunk) Top Ten Shareholder Holdings | Shareholder Name | Shareholder Nature | Number of Shares Held | Percentage (%) | | :--- | :--- | :--- | :--- | | HKSCC NOMINEES LIMITED | Overseas Legal Entity | 392,128,463 | 13.2663 | | G&C VI Limited | Overseas Legal Entity | 190,512,000 | 6.4453 | | HONG KONG SECURITIES CLEARING COMPANY NOMINEES LIMITED | Overseas Legal Entity | 175,555,519 | 5.9393 | | SUMMER BLOOM INVESTMENTS (I) PTE. LTD. | Overseas Legal Entity | 159,160,073 | 5.3846 | | G&C IV Hong Kong Limited | Overseas Legal Entity | 139,319,309 | 4.7134 | | G&C V Limited | Overseas Legal Entity | 97,349,515 | 3.2935 | | Jiaxing Yuxiang Investment Partnership (Limited Partnership) | Other | 87,074,568 | 2.9459 | | CICC Healthcare Mixed Securities Investment Fund | Other | 59,327,580 | 2.0071 | | G&C VII Limited | Overseas Legal Entity | 50,415,120 | 1.7056 | | Shanghai Houshen Investment Center (Limited Partnership) | Other | 45,735,228 | 1.5473 | [Quarterly Financial Statements](index=15&type=section&id=Item%20VI.%20Quarterly%20Financial%20Statements) This section presents the company's unaudited quarterly financial statements, including consolidated balance sheets, income statements, and cash flow statements [Consolidated Financial Statements (PRC GAAP)](index=16&type=section&id=Consolidated%20Financial%20Statements) This section provides unaudited consolidated balance sheets, income statements, and cash flow statements prepared under PRC GAAP, showing total assets of **57.58 billion CNY** and revenue of **8.47 billion CNY** for Q1 2022 Key Consolidated Balance Sheet Items (March 31, 2022) | Item | Amount (CNY) | | :--- | :--- | | Total Assets | 57,582,930,874.69 | | Total Liabilities | 16,935,154,066.16 | | Owners' Equity Attributable to Shareholders of Listed Company | 40,364,486,821.13 | Key Consolidated Income Statement Items (Q1 2022) | Item | Amount (CNY) | | :--- | :--- | | Total Operating Revenue | 8,474,419,333.59 | | Operating Profit | 2,004,959,729.24 | | Net Profit | 1,655,950,521.89 | | Net Profit Attributable to Parent Company Shareholders | 1,642,947,345.12 | Key Consolidated Cash Flow Statement Items (Q1 2022) | Item | Amount (CNY) | | :--- | :--- | | Net Cash Flow from Operating Activities | 497,469,053.50 | | Net Cash Flow from Investing Activities | -1,990,058,578.52 | | Net Cash Flow from Financing Activities | 387,302,550.67 | | Net Increase in Cash and Cash Equivalents | -1,148,811,394.45 | [IFRS Financial Statements and Adjustments](index=25&type=section&id=Condensed%20Quarterly%20Consolidated%20Financial%20Statements%20Prepared%20in%20Accordance%20with%20IFRS) This section presents unaudited condensed quarterly consolidated financial statements prepared under IFRS, detailing the reconciliation from IFRS net profit to adjusted non-IFRS net profit, which was **2.053 billion CNY** in Q1 2022 Reconciliation of Adjusted Non-IFRS Net Profit Attributable to Shareholders of Listed Company (Thousand CNY) | Item | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | **1,642,947** | **1,499,806** | | Add: Share-based compensation expenses | 180,469 | 126,281 | | Add: Amortization of intangible assets acquired through business combinations | 14,463 | 11,245 | | Add: Fair value changes (gains)/losses on derivative financial instruments related to convertible bonds | (82,795) | 451,091 | | Add: Realized and unrealized losses/(gains) on equity investments | 293,660 | (1,024,326) | | Other adjustments | 3,901 | 36,518 | | **Adjusted Non-IFRS Net Profit Attributable to Shareholders of Listed Company** | **2,052,645** | **1,104,668** |

Financial Performance - Revenue for 2021 reached RMB 22,902,385 thousand, a 38.5% increase from RMB 16,535,431 thousand in 2020[7] - Gross profit for 2021 was RMB 8,265,515 thousand, with a gross margin of 36.1%, down from 37.8% in 2020[7] - Net profit attributable to shareholders for 2021 was RMB 5,097,155 thousand, representing a 72.1% increase from RMB 2,960,235 thousand in 2020[7] - Adjusted EBITDA for 2021 was RMB 7,623,885 thousand, with an EBITDA margin of 33.3%, up from 28.4% in 2020[7] - Basic earnings per share for 2021 was RMB 1.75, compared to RMB 1.06 in 2020, reflecting a 65.1% increase[7] - The adjusted net profit margin for 2021 was 22.4%, slightly up from 22.0% in 2020[7] - The company reported an adjusted net profit attributable to shareholders of RMB 5,131,309 thousand for 2021, up from RMB 3,637,277 thousand in 2020[7] - The company achieved operating revenue of RMB 22,902.4 million in 2021, representing a year-on-year growth of 38.5%[9] - The net profit attributable to the parent company reached RMB 5,097.2 million, a year-on-year increase of 72.2%[9] - The company reported a significant increase in revenue, achieving a total of 51 billion RMB for the fiscal year 2021, marking a year-on-year growth of 20%[126] Business Expansion and Investments - The company plans to invest RMB 90–100 billion in capital expenditures in 2022 to enhance new molecular research and development capabilities[5] - The company aims to strengthen its global capabilities and scale, continuing to support partners in accelerating new drug development[5] - The company expanded its global operations with 31 operational bases and branches, serving over 5,700 active clients from more than 30 countries[9] - The company is constructing a new formulation and API production base in Delaware, USA, expected to be operational by 2025[11] - The acquisition of UK-based Oxgene was completed, enhancing the company's capabilities in cell and gene therapy production[12] - The company is investing in new capabilities such as PROTAC, oligonucleotides, and antibody-drug conjugates to capture emerging business opportunities[70] - The company completed the acquisition of UK-based Oxgene, enhancing its capabilities in cell and gene therapy with the TESSA™ technology and XLenti solutions, which significantly improve production efficiency and reduce costs[72] - The company is expanding its market presence in Europe and North America, targeting a 30% increase in market share within the next two years[130] Revenue Sources and Client Base - Revenue from US clients was RMB 12,146 million, up 37.1% year-on-year; revenue from European clients was RMB 3,719 million, up 40.3%[10] - Revenue from existing clients amounted to RMB 21,295 million, reflecting a growth of 28.8% year-on-year, while revenue from new clients was RMB 1,608 million[10] - The company achieved revenue from small molecule drug discovery services reached RMB 6,167.5 million, growing by 43.2% year-on-year[15] - The revenue from development and manufacturing (D&M) services was RMB 7,919.7 million, reflecting a 49.9% year-on-year increase[15] - The company added over 1,660 new clients, serving more than 5,700 active clients from over 30 countries, with approximately 29.4% of revenue coming from the top 20 global pharmaceutical companies[73] Operational Efficiency and Cost Management - The company anticipates a certain degree of revenue decline in 2022 due to upgrades in domestic new drug development services[19] - The management team emphasized a focus on operational efficiency, aiming to reduce costs by 15% over the next fiscal year through process optimization[133] - The company is committed to improving customer satisfaction through high-quality, efficient services and strict intellectual property protection[105] - The company aims to enhance its R&D service platform capabilities and scale, with plans to build and expand facilities in various locations, including Nantong, Wuhan, Changzhou, and the United States[103] Research and Development - The company submitted IND applications for 26 drug candidates in 2021, with a total of 144 IND submissions and 110 clinical trial approvals as of December 31, 2021[19] - The company has established a comprehensive pipeline with 13 drug assets targeting rare diseases and rare tumor indications[67] - The company is focused on internal innovation and external acquisitions to enhance its capabilities in cutting-edge technology fields[102] - The company will continue to invest heavily in new drug research and development, focusing on new molecular types such as PROTAC, oligonucleotide drugs, peptides, ADC, bispecific antibodies, and cell and gene therapies[107] Governance and Compliance - The company has a strong governance structure with independent directors overseeing the board's activities[144] - The board consists of 12 members, including 5 executive directors, 2 non-executive directors, and 5 independent non-executive directors[158] - The company has maintained compliance with corporate governance standards, ensuring that at least one independent non-executive director possesses appropriate professional qualifications or expertise in accounting or related financial management[160] - The company has established a compliance department and legal office to oversee internal controls and corporate governance[183] - The board is responsible for guiding and supervising the company's affairs, ensuring effective internal controls and risk management systems are in place[162] Risk Management - The company faces risks from a potential decline in demand for pharmaceutical research services, which could negatively impact business due to reduced client budgets and outsourcing needs[110] - The company is exposed to regulatory risks as the pharmaceutical research service industry is highly regulated, requiring timely adjustments to business strategies in response to policy changes[111] - The company has established a risk management framework to identify, assess, and respond to potential risks impacting operational goals[182] Shareholder Engagement - The company has established effective communication policies with shareholders to ensure proper responses to their opinions and concerns, which are regularly reviewed[195] - The company allows shareholders holding 3% or more of shares to propose temporary resolutions at the annual general meeting, ensuring transparency and engagement[191] - The company emphasizes the importance of effective communication with shareholders to enhance investor relations and understanding of business performance and strategies[194]

Financial Performance - The company's revenue for 2021 was approximately ¥22.90 billion, representing a 38.50% increase compared to ¥16.54 billion in 2020[19]. - The net profit attributable to shareholders for 2021 was approximately ¥5.10 billion, a 72.19% increase from ¥2.96 billion in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥4.06 billion, reflecting a 70.38% increase from ¥2.39 billion in 2020[19]. - The company's total assets at the end of 2021 were approximately ¥55.13 billion, a 19.09% increase from ¥46.29 billion at the end of 2020[19]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥38.49 billion, an 18.46% increase from ¥32.49 billion at the end of 2020[19]. - The net cash flow from operating activities for 2021 was approximately ¥4.59 billion, a 15.49% increase from ¥3.97 billion in 2020[19]. - The company achieved operating revenue of RMB 22,902.39 million in 2021, representing a year-on-year growth of 38.50%[21]. - Basic earnings per share rose by 65.09% to RMB 1.75, and diluted earnings per share increased by 64.76% to RMB 1.73[23]. - The weighted average return on equity was 14.05%, an increase of 1.14 percentage points compared to the previous year[22]. - The company reported a total of RMB 152,675.06 million in investment income, fair value changes, and asset disposal income, which increased by RMB 87,593.77 million compared to the previous year[22]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5.1740 per 10 shares, totaling approximately RMB 1.53 billion (including tax) based on the current total share capital[3]. - The cash dividend policy stipulates that during a mature development stage with no major capital expenditure, at least 80% of the profit distribution should be in cash dividends[166]. - The company aims to ensure that cash dividends in any three consecutive years are no less than 30% of the average distributable profit for those years[166]. Business Strategy and Growth - The company has been focusing on precision medicine and the development of new drug formulations, leveraging advancements in genomic sequencing and big data[19]. - The company is actively expanding its market presence and enhancing its research capabilities through strategic partnerships and acquisitions[19]. - The company issued $300 million of zero-coupon convertible bonds due in 2024, indicating a strategy to raise capital for future growth[19]. - The company plans to establish a new production base in Delaware, USA, expected to be operational by 2025, marking its second base in the U.S.[41]. - The acquisition of OXGENE in the UK will enhance the company's capabilities in cell and gene therapy, improving production efficiency and reducing costs[42]. - The company is investing in new technologies such as AI and automation to enhance operational efficiency and reduce drug development barriers[40]. - The company aims to enhance its CRDMO and CTDMO service capabilities through acquisitions and internal innovation, focusing on cutting-edge technology fields[99]. Market Performance - Revenue from US customers reached RMB 12.146 billion, a year-on-year increase of 37.1%[29]. - Revenue from European customers was RMB 3.719 billion, growing 40.3% year-on-year[29]. - Revenue from Chinese customers amounted to RMB 5.802 billion, reflecting a 40.0% year-on-year growth[29]. - Revenue from other regions reached RMB 1.234 billion, with a year-on-year increase of 40.7%[29]. - Revenue from existing customers totaled RMB 21.295 billion, up 28.8% year-on-year[29]. - Revenue from the top 20 global pharmaceutical companies was RMB 6.733 billion, a 24.1% increase year-on-year[29]. - Revenue from global other customers reached RMB 16.170 billion, growing 45.6% year-on-year[29]. Research and Development - The company completed the synthesis of over 310,000 new compounds in 2021, enhancing early-stage small molecule drug development[47]. - The company’s CRDMO service revenue experienced rapid growth, with small molecule compound discovery service long-tail customer revenue increasing by 71% year-on-year, contributing to a total of 1,666 new drug molecules in the D&M service projects[48]. - The company is committed to improving customer satisfaction through high-quality services and expanding its customer base, particularly targeting long-tail customers[101]. - The company plans to expand its R&D service platform capabilities, including new laboratories and production bases in various locations, such as Nantong and Wuhan[100]. Environmental Responsibility - The company is committed to environmental responsibility and compliance with pollution discharge standards across all its facilities[181]. - The company has implemented a comprehensive waste management strategy, ensuring all hazardous waste is handled by qualified third-party disposal services[183]. - The company has established monitoring plans for emissions, with annual assessments scheduled for various pollutants[182]. - The wastewater treatment facility has a combined capacity of 1,300 m³/d, with a design capacity of 500 m³/d and 800 m³/d for its two systems[186]. - The company has upgraded its wastewater treatment process to include MBR membrane technology, enhancing treatment capacity and effectiveness[198]. Corporate Governance - The company has established a complete governance structure ensuring independence from the actual controller in terms of assets, personnel, finance, and operations[115]. - The company has implemented a long-term mechanism to prevent the controlling shareholder from occupying company funds, ensuring financial independence[115]. - The company has a robust internal control system to ensure independent financial decision-making[115]. - The company is committed to enhancing its corporate governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder rights[114]. Employee Development - The company has established a competitive compensation management and incentive mechanism to promote employee development and growth[159]. - The training program includes a structured training system for employees at all levels, focusing on leadership development and professional skills enhancement[160]. - The Potential Leaders Development Program (PLDP) includes over 10 courses aimed at enhancing leadership skills for high-potential employees[162]. - The company emphasizes continuous updates and iterations of training and selection content to align with business development strategies[165]. Risks and Challenges - The company faces risks from intensified competition in the pharmaceutical research service market, particularly from large pharmaceutical companies and new market entrants[107]. - The company is exposed to risks from international operations, including potential adverse effects from changes in laws, policies, or political environments in foreign markets[109]. - The company acknowledges the potential impact of unforeseen events, such as public health crises or natural disasters, on its operations and has developed a business continuity plan[112].

Financial Performance - Revenue for the six months ended June 30, 2021, was RMB 10,536.6 million, representing a 45.7% increase from RMB 7,231.4 million in 2020[8] - Gross profit for the same period was RMB 3,883.7 million, up 46.1% from RMB 2,658.6 million in 2020, with a gross margin of 36.9%[8] - Adjusted net profit attributable to shareholders was RMB 2,447.9 million, a 67.8% increase from RMB 1,458.8 million in 2020[8] - The net profit for the reporting period increased from RMB 1,727.5 million to RMB 2,692.2 million, a year-on-year increase of 55.8%, with a net profit margin rising from 23.9% to 25.6%[31] - The company reported a total comprehensive income of RMB 2,415,051 thousand, an increase of 36.0% from RMB 1,775,383 thousand in the prior year[179] Customer and Market Growth - The number of active customers exceeded 5,220, with approximately 1,020 new active customers added during the reporting period[9] - Revenue from the top 20 global pharmaceutical companies accounted for 28.2% of total revenue, a 29% year-on-year increase, while revenue from long-tail customers grew by 54%[9] - Revenue from overseas customers was RMB 8,035 million, up 45% year-on-year, while revenue from Chinese customers was RMB 2,501 million, reflecting a 48% increase[11] - The company signed 81 service contracts through the WIND platform, with an average project revenue of USD 1.1 to 1.5 million[12] Assets and Liabilities - Total assets as of June 30, 2021, were RMB 52,177.4 million, a 12.7% increase from RMB 46,291.2 million at the end of 2020[8] - The total liabilities amounted to RMB 15,193.8 million, reflecting an 11.9% increase from RMB 13,572.7 million in 2020[8] - The company's total borrowings as of June 30, 2021, were RMB 2,271.2 million, all due within one year, with floating rate borrowings at RMB 962.6 million and fixed rate borrowings at RMB 1,308.6 million[35] - The debt-to-asset ratio as of June 30, 2021, was 29.1%, slightly down from 29.3% as of December 31, 2020, due to increased retained earnings and net assets[34] Research and Development - Research and development expenses rose from RMB 333.4 million to RMB 404.4 million, reflecting a year-on-year increase of 21.3%, as the company focused on enhancing capabilities in biocatalysis and automated chemistry[26] - The company submitted 7 IND applications and received 8 clinical trial approvals during the reporting period, with a total of 126 IND submissions and 99 CTAs to date[13] - The company continues to invest in R&D, with R&D expenses amounting to RMB 404.4 million during the reporting period[195] Operational Efficiency - The adjusted net profit margin for the reporting period was 23.2%, compared to 20.2% in the previous year[8] - The company achieved total revenue of RMB 10,536.6 million for the six months ended June 30, 2021, representing a year-on-year growth of 45.7%[11] - The adjusted EBITDA for the six months ended June 30, 2021, was RMB 3,942.4 million, compared to RMB 2,600.3 million for the same period in 2020, reflecting a growth in operational performance[39] Employee and Management - The company has a workforce of 28,542 employees, including 9,179 with master's degrees and 1,149 with doctoral degrees[10] - The management team, led by Dr. Li Ge, possesses extensive industry experience and is committed to transforming the drug discovery and development industry[60] - The company aims to establish a long-term incentive mechanism to attract and retain talent, ensuring the sustainable development of the company[116] Strategic Initiatives - The acquisition of UK-based Oxgene enhances the company's CTDMO capabilities and provides advanced technologies for high-quality AAV production, supporting better service for global clients[58] - The company is expanding its global footprint with new facilities, including a second API and drug production facility in Delaware, USA, and a new 15,300 square meter cell and gene therapy facility in Shanghai[58] - The company is investing in new capabilities and capacities, including PROTAC, oligonucleotides, peptides, ADCs, bispecific antibodies, and cell and gene therapies to seize new business opportunities[57] Risks and Challenges - The company faces risks from potential declines in market demand for pharmaceutical R&D services, which could negatively impact business if industry trends slow or outsourcing rates decrease[77] - Regulatory changes in the pharmaceutical R&D services industry pose a risk, as the company must adapt to evolving policies and regulations to avoid adverse impacts on operations[78] - International operations expose the company to risks from changes in foreign laws, policies, and geopolitical tensions, which could disrupt business continuity[81] Financial Management - The company plans to maintain a prudent financial management approach to balance guaranteed principal, liquidity, and yield in its investment activities[45] - The company has raised approximately RMB 2,130.3 million from its A-share listing, with RMB 697.2 million remaining unutilized as of June 30, 2021[87] - The company has utilized a total of approximately $7.29 billion for various purposes, including mergers and acquisitions, operational funding, and debt repayment[101]

Financial Performance - In 2020, WuXi AppTec's revenue increased by 28.5% year-on-year, reaching RMB 16.535 billion[7]. - Adjusted net profit attributable to the parent company rose by 48.1% year-on-year to RMB 3.565 billion[7]. - The company achieved a revenue of RMB 16,535.4 million for the year ended December 31, 2020, representing a year-on-year growth of 28.5%[13]. - The net profit attributable to the parent company was RMB 2,960.2 million, reflecting a year-on-year increase of 59.6%[13]. - The gross profit margin decreased to 37.8% from 38.9% in the previous year[13]. - Revenue from existing customers contributed RMB 15,503.8 million, a year-on-year growth of 32.1%[13]. - The company achieved a comprehensive gross profit of RMB 6,255.0 million, representing a 24.9% increase compared to the same period in 2019[25]. - The gross profit from CDMO services reached RMB 2,156.8 million, with a year-on-year growth of 44.2%[27]. - The gross profit from clinical research and other CRO services decreased to RMB 165.4 million, a decline of 35.0% year-on-year[29]. - The company reported a foreign exchange loss of RMB 411.1 million in 2020, compared to a gain of RMB 20.7 million in 2019, due to significant fluctuations in the RMB/USD exchange rate[101]. Customer Growth and Market Expansion - The company added over 1,300 new customers, with active customers exceeding 4,200 during the reporting period[7]. - The company continues to strengthen its capabilities in the US for laboratory and clinical research services, resulting in an increasing backlog of orders[7]. - The company has expanded its customer base by over 1,300 new clients, serving more than 4,200 clients from over 30 countries, with 32.8% of revenue coming from the top 20 global pharmaceutical companies[71]. - 93.8% of the company's revenue is derived from existing clients, while 6.2% comes from new clients, indicating strong customer loyalty[71]. - The company is focused on expanding its drug quality analysis services through the acquisition of Nanjing Mingjie Biomedicine Testing Co., Ltd.[70]. Strategic Investments and Acquisitions - The company acquired OXGENE, a UK-based cell and gene therapy CRO, and announced the acquisition of a formulation production facility in Couvet, Switzerland[7]. - The company has successfully integrated several acquisitions, including AppTec and WuXi Clinical Development, enhancing its drug development and production service chain[70]. - The company completed the acquisition of Nanjing Mingjie Biomedical Testing Co., Ltd. and Shanghai Mingjie Pharmaceutical Technology Co., Ltd. during the reporting period[199]. Research and Development - The company is committed to enhancing R&D service capabilities and scaling operations globally to support innovative drug development[7]. - The company is investing heavily in R&D, allocating 25% of its revenue to research and development activities, which is expected to enhance its competitive edge in the biotech sector[112]. - The company plans to invest in new capabilities and production capacities, focusing on areas such as PROTAC, oligonucleotides, peptides, ADCs, and cell and gene therapies to seize new business opportunities[91]. Operational Efficiency and Cost Management - The company executed a business continuity plan effectively, ensuring the health and safety of its operations during the COVID-19 pandemic[7]. - The company reported a 30% increase in operational efficiency due to recent process optimizations, which is expected to contribute positively to the bottom line[112]. - The company has optimized the manufacturing process for plasmids and lentiviruses, further reducing production costs[17]. Financial Management and Capital Structure - The total assets increased to RMB 46,291.2 million from RMB 29,239.1 million year-on-year[11]. - The company’s cash and bank balances rose to RMB 10,228.1 million, up from RMB 5,223.3 million in the previous year[11]. - The debt-to-asset ratio decreased to 29.3% as of December 31, 2020, from 40.5% in 2019, primarily due to an increase in total assets from the issuance of H shares and A shares[45]. - The company intends to use part of the proceeds from the private placement of A-shares to repay existing debt, thereby reducing interest expenses and optimizing its financing structure[74]. Corporate Governance and Management - The company has a strong board with members holding significant experience in investment and corporate governance, enhancing strategic decision-making capabilities[116]. - The company emphasizes independent judgment in its governance structure, with multiple independent directors on the board[119][120][121]. - The company has established a compliance department and legal office to oversee internal controls and corporate governance, ensuring adherence to applicable laws and regulations[157]. Market Outlook and Future Plans - The company has set a future outlook with a revenue guidance of 50 billion RMB for the next fiscal year, indicating a projected growth rate of 13.6%[110]. - The company aims to enhance its competitive advantage through an integrated end-to-end drug development service platform, benefiting from the rapid growth of the global drug development outsourcing market[67]. - The company plans to continue its strategic investments in healthcare sectors, including medical devices and drug development, to enhance its market position[51]. Risk Management - The company faces risks from potential declines in demand for pharmaceutical research services, which could negatively impact its business if industry trends slow down[94]. - The company operates in a highly regulated industry, and any failure to adapt to changes in industry policies and regulations could adversely affect its operations[95]. - The company is experiencing intensified competition in the global pharmaceutical research services market, which may pose risks if it cannot maintain its competitive advantages[96].